CA2369009A1 - Factor for regulation of neurite growth - Google Patents
Factor for regulation of neurite growth Download PDFInfo
- Publication number
- CA2369009A1 CA2369009A1 CA002369009A CA2369009A CA2369009A1 CA 2369009 A1 CA2369009 A1 CA 2369009A1 CA 002369009 A CA002369009 A CA 002369009A CA 2369009 A CA2369009 A CA 2369009A CA 2369009 A1 CA2369009 A1 CA 2369009A1
- Authority
- CA
- Canada
- Prior art keywords
- rar
- ngf
- neurons
- agonist
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1783—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- High Energy & Nuclear Physics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9907461.9A GB9907461D0 (en) | 1999-03-31 | 1999-03-31 | Neurite regeneration |
| GB9907461.9 | 1999-03-31 | ||
| PCT/GB2000/001211 WO2000057900A2 (en) | 1999-03-31 | 2000-03-30 | Factor for regulation of neurite growth |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2369009A1 true CA2369009A1 (en) | 2000-10-05 |
Family
ID=10850746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002369009A Abandoned CA2369009A1 (en) | 1999-03-31 | 2000-03-30 | Factor for regulation of neurite growth |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20070054961A1 (https=) |
| EP (2) | EP1180039B1 (https=) |
| JP (1) | JP2002540164A (https=) |
| KR (1) | KR20010104401A (https=) |
| CN (1) | CN100350970C (https=) |
| AT (1) | ATE342728T1 (https=) |
| AU (1) | AU770394B2 (https=) |
| CA (1) | CA2369009A1 (https=) |
| DE (1) | DE60031396T2 (https=) |
| GB (2) | GB9907461D0 (https=) |
| WO (1) | WO2000057900A2 (https=) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60132436T2 (de) * | 2000-03-30 | 2008-04-17 | Oxford Biomedica (Uk) Ltd. | Retinolsäure-rezeptor beta-2 und gentherapievektoren für die behandlung von neurologischen erkrankungen |
| GB0103998D0 (en) * | 2001-02-19 | 2001-04-04 | King S College London | Method |
| US7490472B2 (en) | 2003-02-11 | 2009-02-17 | Statoil Asa | Efficient combined cycle power plant with CO2 capture and a combustor arrangement with separate flows |
| EP2931899A1 (en) | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
| DK2931897T3 (en) | 2012-12-12 | 2018-02-05 | Broad Inst Inc | CONSTRUCTION, MODIFICATION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTICAL APPLICATIONS |
| MX2015017312A (es) | 2013-06-17 | 2017-04-10 | Broad Inst Inc | Suministro y uso de composiciones, vectores y sistemas crispr-cas para la modificación dirigida y terapia hepáticas. |
| KR20250012194A (ko) | 2013-06-17 | 2025-01-23 | 더 브로드 인스티튜트, 인코퍼레이티드 | 바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용 |
| KR20160019553A (ko) | 2013-06-17 | 2016-02-19 | 더 브로드 인스티튜트, 인코퍼레이티드 | 유사분열 후 세포의 질병 및 장애를 표적화하고 모델링하기 위한 시스템, 방법 및 조성물의 전달, 유전자 조작 및 최적화 |
| JP6793547B2 (ja) | 2013-12-12 | 2020-12-02 | ザ・ブロード・インスティテュート・インコーポレイテッド | 最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物 |
| MX2016007325A (es) | 2013-12-12 | 2017-07-19 | Broad Inst Inc | Composiciones y metodos de uso de sistemas crispr-cas en desordenes debidos a repeticion de nucleotidos. |
| AU2014361781B2 (en) | 2013-12-12 | 2021-04-01 | Massachusetts Institute Of Technology | Delivery, use and therapeutic applications of the CRISPR -Cas systems and compositions for genome editing |
| BR112016013207A2 (pt) | 2013-12-12 | 2017-09-26 | Massachusetts Inst Technology | administração, uso e aplicações terapêuticas dos sistemas crispr-cas e composições para o hbv e distúrbios e doenças virais |
| EP3080259B1 (en) | 2013-12-12 | 2023-02-01 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation |
| EP3686279B1 (en) | 2014-08-17 | 2023-01-04 | The Broad Institute, Inc. | Genome editing using cas9 nickases |
| WO2016049163A2 (en) | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder |
| WO2016049258A2 (en) | 2014-09-25 | 2016-03-31 | The Broad Institute Inc. | Functional screening with optimized functional crispr-cas systems |
| EP3889260A1 (en) | 2014-12-12 | 2021-10-06 | The Broad Institute, Inc. | Protected guide rnas (pgrnas) |
| WO2016094874A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Escorted and functionalized guides for crispr-cas systems |
| WO2016094880A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs) |
| WO2016094872A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Dead guides for crispr transcription factors |
| CN107207488B (zh) | 2014-12-17 | 2020-11-17 | 伦敦皇家学院 | 作为视黄酸受体β(RARβ)激动剂的双环杂芳基-杂芳基-苯甲酸化合物 |
| EP3234192B1 (en) | 2014-12-19 | 2021-07-14 | The Broad Institute, Inc. | Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing |
| WO2016106236A1 (en) | 2014-12-23 | 2016-06-30 | The Broad Institute Inc. | Rna-targeting system |
| WO2016106244A1 (en) | 2014-12-24 | 2016-06-30 | The Broad Institute Inc. | Crispr having or associated with destabilization domains |
| WO2016201368A1 (en) | 2015-06-10 | 2016-12-15 | The Broad Institute Inc. | Antibodies, compounds and screens for identifying and treating cachexia or pre-cachexia |
| CA3012607A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Crispr enzymes and systems |
| EP4159856A1 (en) | 2015-06-18 | 2023-04-05 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| TWI813532B (zh) | 2015-06-18 | 2023-09-01 | 美商博得學院股份有限公司 | 降低脱靶效應的ｃｒｉｓｐｒ酶突變 |
| WO2016205745A2 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Cell sorting |
| WO2017031370A1 (en) | 2015-08-18 | 2017-02-23 | The Broad Institute, Inc. | Methods and compositions for altering function and structure of chromatin loops and/or domains |
| US12241053B2 (en) | 2015-10-09 | 2025-03-04 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| CN109153980B (zh) | 2015-10-22 | 2023-04-14 | 布罗德研究所有限公司 | Vi-b型crispr酶和系统 |
| EP3368687B1 (en) | 2015-10-27 | 2021-09-29 | The Broad Institute, Inc. | Compositions and methods for targeting cancer-specific sequence variations |
| WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
| WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
| WO2017075478A2 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures |
| WO2017106657A1 (en) | 2015-12-18 | 2017-06-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
| CN110382692A (zh) | 2016-04-19 | 2019-10-25 | 博德研究所 | 新型crispr酶以及系统 |
| US20200263190A1 (en) | 2016-04-19 | 2020-08-20 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
| EP3445853A1 (en) | 2016-04-19 | 2019-02-27 | The Broad Institute, Inc. | Cpf1 complexes with reduced indel activity |
| CA3028158A1 (en) | 2016-06-17 | 2017-12-21 | The Broad Institute, Inc. | Type vi crispr orthologs and systems |
| GB201610867D0 (en) | 2016-06-22 | 2016-08-03 | King S College London | Crystalline forms of a therapeutic compound and processes for their preparation |
| US12595478B2 (en) | 2016-06-29 | 2026-04-07 | The Broad Institute, Inc. | Crispr-Cas systems having destabilization domain |
| CN110312799A (zh) | 2016-08-17 | 2019-10-08 | 博德研究所 | 新型crispr酶和系统 |
| WO2018035388A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
| US20190262399A1 (en) | 2016-09-07 | 2019-08-29 | The Broad Institute, Inc. | Compositions and methods for evaluating and modulating immune responses |
| WO2018064208A1 (en) | 2016-09-28 | 2018-04-05 | The Broad Institute, Inc. | Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof |
| US12447213B2 (en) | 2016-10-07 | 2025-10-21 | The Broad Institute, Inc. | Modulation of novel immune checkpoint targets |
| ES2950676T3 (es) | 2017-01-30 | 2023-10-11 | Kws Saat Se & Co Kgaa | Reparación de enlace de plantillas a endonucleasas para modificación de genes |
| AU2018234825B2 (en) | 2017-03-15 | 2020-12-17 | Massachusetts Institute Of Technology | Novel CAS13B orthologues CRISPR enzymes and systems |
| AU2018251801B2 (en) | 2017-04-12 | 2024-11-07 | Massachusetts Institute Of Technology | Novel type VI CRISPR orthologs and systems |
| US12350368B2 (en) | 2017-04-14 | 2025-07-08 | The Broad Institute, Inc. | Delivery of large payloads |
| US11591601B2 (en) | 2017-05-05 | 2023-02-28 | The Broad Institute, Inc. | Methods for identification and modification of lncRNA associated with target genotypes and phenotypes |
| EP3625342B1 (en) | 2017-05-18 | 2022-08-24 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
| WO2019010422A1 (en) | 2017-07-07 | 2019-01-10 | The Broad Institute, Inc. | ANTIVIRAL THERAPY BASED ON THE CRISPR SYSTEM |
| JP2020535802A (ja) | 2017-09-21 | 2020-12-10 | ザ・ブロード・インスティテュート・インコーポレイテッド | 標的化核酸編集のための系、方法、及び組成物 |
| EP3692152B1 (en) | 2017-10-04 | 2025-09-03 | The Broad Institute, Inc. | Methods and compositions for altering function and structure of chromatin loops and/or domains |
| US12227742B2 (en) | 2017-10-23 | 2025-02-18 | The Broad Institute, Inc. | Nucleic acid modifiers |
| US11547614B2 (en) | 2017-10-31 | 2023-01-10 | The Broad Institute, Inc. | Methods and compositions for studying cell evolution |
| WO2019094984A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods for determining spatial and temporal gene expression dynamics during adult neurogenesis in single cells |
| EP3710039A4 (en) | 2017-11-13 | 2021-08-04 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH |
| WO2019126709A1 (en) | 2017-12-22 | 2019-06-27 | The Broad Institute, Inc. | Cas12b systems, methods, and compositions for targeted dna base editing |
| US10968257B2 (en) | 2018-04-03 | 2021-04-06 | The Broad Institute, Inc. | Target recognition motifs and uses thereof |
| CN113286884A (zh) | 2018-08-07 | 2021-08-20 | 博德研究所 | 新型cas12b酶和系统 |
| WO2020041380A1 (en) | 2018-08-20 | 2020-02-27 | The Broad Institute, Inc. | Methods and compositions for optochemical control of crispr-cas9 |
| CA3124110A1 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Crispr-associated transposase systems and methods of use thereof |
| US12215382B2 (en) | 2019-03-01 | 2025-02-04 | The General Hospital Corporation | Liver protective MARC variants and uses thereof |
| US12534714B2 (en) | 2019-03-18 | 2026-01-27 | The Broad Institute, Inc. | Type VII CRISPR proteins and systems |
| WO2020236972A2 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Non-class i multi-component nucleic acid targeting systems |
| GB201907647D0 (en) * | 2019-05-30 | 2019-07-17 | King S College London | Therapeutic methods |
| US12297426B2 (en) | 2019-10-01 | 2025-05-13 | The Broad Institute, Inc. | DNA damage response signature guided rational design of CRISPR-based systems and therapies |
| CN119562762A (zh) | 2022-04-04 | 2025-03-04 | 加利福尼亚大学董事会 | 遗传互补组合物和方法 |
| WO2025072383A1 (en) | 2023-09-25 | 2025-04-03 | The Broad Institute, Inc. | Viral open reading frames, uses thereof, and methods of detecting the same |
| WO2025097055A2 (en) | 2023-11-02 | 2025-05-08 | The Broad Institute, Inc. | Compositions and methods of use of t cells in immunotherapy |
| WO2025129158A1 (en) | 2023-12-15 | 2025-06-19 | The Broad Institute, Inc. | Engineered arc delivery vesicles and uses thereof |
| WO2025250808A1 (en) | 2024-05-29 | 2025-12-04 | The Brigham And Women’S Hospital, Inc. | Anti-crispr delivery compositions and methods |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| JP2608540B2 (ja) | 1982-05-19 | 1997-05-07 | ギスト ブロカデス ナ−ムロ−ゼ フエンノ−トチヤツプ | クルイベロミセス種のためのクローニング系 |
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| IE58014B1 (en) | 1983-07-06 | 1993-06-16 | Gist Brocades Nv | Molecular cloning and expression in industrial microorganism species |
| US4885249A (en) | 1984-12-05 | 1989-12-05 | Allelix, Inc. | Aspergillus niger transformation system |
| DE3650783T2 (de) | 1985-04-15 | 2004-07-15 | Dsm Ip Assets B.V. | Verwendung des Glucoamylasepromotors aus Apergillus |
| NO872932L (no) | 1986-07-18 | 1988-01-19 | Gist Brocades Nv | Fremgangsmaate for fremstilling av proteiner med faktorviiiaktivitet ved hjelp av mikrobielle vertsceller, eksprimeringsvektorer, vertsceller, antibiotika. |
| HU201870B (en) * | 1987-01-16 | 1991-01-28 | Us Health | Process for producing pharmaceutical compositions containing isoretinoin as active component |
| US4808630A (en) * | 1987-01-16 | 1989-02-28 | United States Of America | Method of treating psychotic illnesses |
| NO302485B1 (no) | 1987-07-28 | 1998-03-09 | Gist Brocades Bv | Fremgangsmåte for fremstilling av et polypeptid av interesse i en Klyveromyces vertscelle, transformert Klyveromyces vertscelle og anvendelse derav, plasmid og DNA konstruksjon |
| KR100225087B1 (ko) | 1990-03-23 | 1999-10-15 | 한스 발터라벤 | 피타아제의 식물내 발현 |
| CA2211142A1 (en) * | 1995-01-23 | 1996-08-01 | Ligand Pharmaceuticals Incorporated | Human retinoid x receptor - gamma (hrxr-gamma) |
| IT1276459B1 (it) * | 1995-06-30 | 1997-10-31 | Khodor Ammar | Composizioni cosmetiche con proprieta' antimicotiche, efficaci contro la psoriasi e la caduta dei capelli e metodo cosmetico per la |
| FR2739557B1 (fr) * | 1995-10-09 | 1997-11-14 | Cird Galderma | Utilisation d'un ligand agoniste specifique rar-gamma |
| US5965606A (en) * | 1995-12-29 | 1999-10-12 | Allergan Sales, Inc. | Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity |
| WO1998049271A1 (en) | 1997-04-25 | 1998-11-05 | American Home Products Corporation | Human neuronal cell line |
| AU1122099A (en) * | 1997-10-27 | 1999-05-17 | Curis, Inc. | Enhancement of morphogen activity |
-
1999
- 1999-03-31 GB GBGB9907461.9A patent/GB9907461D0/en not_active Ceased
-
2000
- 2000-03-30 JP JP2000607650A patent/JP2002540164A/ja active Pending
- 2000-03-30 AT AT00918991T patent/ATE342728T1/de not_active IP Right Cessation
- 2000-03-30 CA CA002369009A patent/CA2369009A1/en not_active Abandoned
- 2000-03-30 EP EP00918991A patent/EP1180039B1/en not_active Expired - Lifetime
- 2000-03-30 DE DE60031396T patent/DE60031396T2/de not_active Expired - Fee Related
- 2000-03-30 AU AU39755/00A patent/AU770394B2/en not_active Ceased
- 2000-03-30 CN CNB008080887A patent/CN100350970C/zh not_active Expired - Fee Related
- 2000-03-30 KR KR1020017012263A patent/KR20010104401A/ko not_active Withdrawn
- 2000-03-30 EP EP06076367A patent/EP1762243A1/en not_active Withdrawn
- 2000-03-30 GB GB0123381A patent/GB2365772A/en not_active Withdrawn
- 2000-03-30 WO PCT/GB2000/001211 patent/WO2000057900A2/en not_active Ceased
-
2006
- 2006-09-25 US US11/526,458 patent/US20070054961A1/en not_active Abandoned
-
2009
- 2009-09-30 US US12/570,659 patent/US20100317109A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN100350970C (zh) | 2007-11-28 |
| DE60031396T2 (de) | 2007-08-30 |
| DE60031396D1 (de) | 2006-11-30 |
| WO2000057900A2 (en) | 2000-10-05 |
| US20100317109A1 (en) | 2010-12-16 |
| AU770394B2 (en) | 2004-02-19 |
| EP1180039A2 (en) | 2002-02-20 |
| EP1762243A1 (en) | 2007-03-14 |
| KR20010104401A (ko) | 2001-11-26 |
| US20070054961A1 (en) | 2007-03-08 |
| WO2000057900A3 (en) | 2001-02-15 |
| JP2002540164A (ja) | 2002-11-26 |
| AU3975500A (en) | 2000-10-16 |
| EP1180039B1 (en) | 2006-10-18 |
| GB0123381D0 (en) | 2001-11-21 |
| ATE342728T1 (de) | 2006-11-15 |
| CN1355706A (zh) | 2002-06-26 |
| GB9907461D0 (en) | 1999-05-26 |
| GB2365772A (en) | 2002-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1180039B1 (en) | Composition for the treatment of a neurological disorder | |
| Castro et al. | Induction of cell cycle arrest and morphological differentiation by Nurr1 and retinoids in dopamine MN9D cells | |
| Perlmann et al. | Nuclear receptors in Sicily: all in the famiglia | |
| Gainetdinov et al. | Re-evaluation of the role of the dopamine transporter in dopamine system homeostasis | |
| US6653322B1 (en) | Therapeutic combinations of RAR antagonists and RXR agonists and use thereof | |
| Langlois et al. | Impact of antipsychotic drug administration on the expression of nuclear receptors in the neocortex and striatum of the rat brain | |
| WO1998008546A9 (en) | Therapeutic combinations of rar antagonists and rxr agonists and use thereof | |
| US20100087532A1 (en) | Modulation of signal transduction | |
| Liu et al. | Upregulation of annexins I, II, and V after traumatic spinal cord injury in adult rats | |
| Menéndez-Gutiérrez et al. | The multi-faceted role of retinoid X receptor in bone remodeling | |
| Prakash | Developmental pathways linked to the vulnerability of adult midbrain dopaminergic neurons to neurodegeneration | |
| Stark et al. | Distribution of TGF-β, the TGF-β type I receptor and the R-II receptor in peripheral nerves and mechanoreceptors; observations on changes after traumatic injury | |
| Feart et al. | Differential effect of retinoic acid and triiodothyronine on the age-related hypo-expression of neurogranin in rat | |
| WO2002100827A2 (en) | Method for increasing the survival of dopamine secreting cells | |
| EP1268835B1 (en) | Retinoic acid receptor beta-2 and gene therapy vectors for the treatment of neurological disorders | |
| US20070213290A1 (en) | Neurite regeneration | |
| Ingram et al. | Glial glutamate transporter mRNAs in the genetically absence epilepsy rat from Strasbourg | |
| Narita et al. | Role of spinal voltage-dependent calcium channel α2δ-1 subunit in the expression of a neuropathic pain-like state in mice | |
| US20060063258A1 (en) | Retinoic acid receptor beta-2, its agonists, and gene therapy vectors for the treatment of neurological disorders | |
| Akinshola et al. | Involvement of non-NMDA receptors in the rescue of weaver cerebellar granule neurons and sensitivity to ethanol of cerebellar AMPA receptors in oocytes | |
| De Groot et al. | Thyroid hormones in brain development and function | |
| Lindsey | 5.3 Nongenomic TH Signaling | |
| Bock et al. | LDL receptor-related protein 1 (LRP1) | |
| Liu | Developmental regulation of DA11, a fatty acid-binding protein in rat brain | |
| Tian | The molecular mechanism of loss of glial glutamate transporter EAAT2 in neurodegenerative disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |